CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 19, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 18, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a
LUCIDITY met FDA -agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) LUCIDITY met all secondary endpoints showing consistent, highly statistically significant, and clinically
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 17, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026.
Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August or early September 2026 Cash runway expected to fund operations into 2028
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its second quarter 2026 financial results on Thursday, August 6, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2026-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS (ENCALS) Meeting 2026, held
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2026-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago, IL.
Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related to disease progression, including pancreatic beta cell function, glycemic
Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: Bank of America’s 2026 Health Care
The Expanded Access Program allows eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery access to avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor antagonist Avexitide is being evaluated in the pivotal Phase 3 LUCIDITY clinical
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 8, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 15, 2026,
Last participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on track; anticipated in Q3 2026 LUCIDITY is evaluating the FDA-agreed-upon primary outcome of reduction in the composite of Level 2 and Level 3
Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into